2.50
Hdl Handle:
http://hdl.handle.net/10541/59253
Title:
Clinical experience with gefitinib in Indian patients.
Authors:
Parikh, Purvish; Chang, Alex; Nag, Shona; Digumarti, Raghunadharao; Bhattacharyya, Gouri Shankar; Doval, Dinesh Chandra; Babu, Govind; Chacko, Raju Titus; Advani, Suresh; Ranade, Anantbhushan; Aggarwal, Shyam; Jagannathan, Ramesh; Hargreaves, Laura; Thatcher, Nick
Abstract:
INTRODUCTION: Treatment options are limited in patients with advanced or refractory non-small cell lung cancer and lead to suboptimal outcome and/or benefit. The epidermal growth factor tyrosine kinase inhibitor gefitinib (IRESSA) has been approved in many countries. Increased responsiveness to gefitinib has been demonstrated in particular subsets of patients, for example never smokers and patients of Asian origin. However, to date, little is known of its use specifically in patients from India. METHODS: Retrospective ad hoc analysis of clinical data from experience with gefitinib in patients with advanced NSCLC from India enrolled in the IRESSA Survival Evaluation in Lung (ISEL) study (n = 77) or included in the gefitinib expanded-access program in India (n = 133). RESULTS: Among Indian patients enrolled in the ISEL study, median survival was 6.4 months with gefitinib and 5.1 month with placebo. The objective response rate in Indian patients was 14% with gefitinib versus 0% with placebo. In ISEL, tolerability data from Indian patients were consistent with the overall study population. In the Indian gefitinib expanded-access program, median survival was 6 months and gefitinib was well tolerated. CONCLUSIONS: Gefitinib seems well tolerated in Indian patients with advanced NSCLC, with some clinical benefit observed.
Affiliation:
Tata Memorial Hospital, Mumbai, India. purvish@rediffmail.com
Citation:
Clinical experience with gefitinib in Indian patients. 2008, 3 (4):380-5 J Thorac Oncol
Journal:
Journal of Thoracic Oncology
Issue Date:
Apr-2008
URI:
http://hdl.handle.net/10541/59253
DOI:
10.1097/JTO.0b013e318168f794
PubMed ID:
18379356
Type:
Article
Language:
en
ISSN:
1556-1380
Appears in Collections:
All Christie Publications ; Medical Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorParikh, Purvish-
dc.contributor.authorChang, Alex-
dc.contributor.authorNag, Shona-
dc.contributor.authorDigumarti, Raghunadharao-
dc.contributor.authorBhattacharyya, Gouri Shankar-
dc.contributor.authorDoval, Dinesh Chandra-
dc.contributor.authorBabu, Govind-
dc.contributor.authorChacko, Raju Titus-
dc.contributor.authorAdvani, Suresh-
dc.contributor.authorRanade, Anantbhushan-
dc.contributor.authorAggarwal, Shyam-
dc.contributor.authorJagannathan, Ramesh-
dc.contributor.authorHargreaves, Laura-
dc.contributor.authorThatcher, Nick-
dc.date.accessioned2009-04-02T16:11:37Z-
dc.date.available2009-04-02T16:11:37Z-
dc.date.issued2008-04-
dc.identifier.citationClinical experience with gefitinib in Indian patients. 2008, 3 (4):380-5 J Thorac Oncolen
dc.identifier.issn1556-1380-
dc.identifier.pmid18379356-
dc.identifier.doi10.1097/JTO.0b013e318168f794-
dc.identifier.urihttp://hdl.handle.net/10541/59253-
dc.description.abstractINTRODUCTION: Treatment options are limited in patients with advanced or refractory non-small cell lung cancer and lead to suboptimal outcome and/or benefit. The epidermal growth factor tyrosine kinase inhibitor gefitinib (IRESSA) has been approved in many countries. Increased responsiveness to gefitinib has been demonstrated in particular subsets of patients, for example never smokers and patients of Asian origin. However, to date, little is known of its use specifically in patients from India. METHODS: Retrospective ad hoc analysis of clinical data from experience with gefitinib in patients with advanced NSCLC from India enrolled in the IRESSA Survival Evaluation in Lung (ISEL) study (n = 77) or included in the gefitinib expanded-access program in India (n = 133). RESULTS: Among Indian patients enrolled in the ISEL study, median survival was 6.4 months with gefitinib and 5.1 month with placebo. The objective response rate in Indian patients was 14% with gefitinib versus 0% with placebo. In ISEL, tolerability data from Indian patients were consistent with the overall study population. In the Indian gefitinib expanded-access program, median survival was 6 months and gefitinib was well tolerated. CONCLUSIONS: Gefitinib seems well tolerated in Indian patients with advanced NSCLC, with some clinical benefit observed.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subjectRandomized Controlled Trialen
dc.subjectNon-Small-Cell Lung Canceren
dc.subject.meshAdenocarcinoma-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshCarcinoma, Large Cell-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshCarcinoma, Squamous Cell-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshIndia-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMaximum Tolerated Dose-
dc.subject.meshMiddle Aged-
dc.subject.meshPrognosis-
dc.subject.meshQuinazolines-
dc.subject.meshReceptor, Epidermal Growth Factor-
dc.subject.meshRetrospective Studies-
dc.subject.meshSurvival Rate-
dc.titleClinical experience with gefitinib in Indian patients.en
dc.typeArticleen
dc.contributor.departmentTata Memorial Hospital, Mumbai, India. purvish@rediffmail.comen
dc.identifier.journalJournal of Thoracic Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.